

- 1 Alberti S, Chiesa A, Andrisano C, Serretti A. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression. *J Clin Psychopharmacol* 2015;35:296-303
- Dunlop BW et al. Symptomatic and functional improvement in employed depressed patients: A double-blind clinical trial of desvenlafaxine versus placebo. *J Clin Psychopharmacol* 2011;31(5):569-76
- Cooper JA et al. Resolution of sleepiness and fatigue: A comparison of bupropion and SSRIs in subjects with MDD achieving remission at doses approved in the EU. *J Psychopharmacol* 2014;28:118-124
- Mago R et al. Safety and tolerability of Levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. *Clin Drug Investig* 2013; 33(10): 761-771
- Sambunaris A et al. A phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran ER in Patients with Major Depressive Disorder. *J Clin Psychopharmacol* 2014;34(1):47-56
- Thase ME et al. Effects of levomilnacipran ER on motivation/energy and functioning in adults with major depressive disorder. *Int Clin Psychopharmacol* 2016;31:332-340
- McIntyre RS et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants. *Expert Opin Pharmacother* 2009;10 (18) :3061-3075
- Citrome L. Vortioxetine for major depressive disorder: ...a systematic review...what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2014;68:60-82
- 2 Alberti S, Chiesa A, Andrisano C, Serretti A. Insomnia and somnolence associated with second-gen antidepressants during the treatment of major depression. *J Clin Psychopharmacol* 2015;35:296-303
- McIntyre RS et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants. *Expert Opin Pharmacother* 2009;10 (18) :3061-3075
- 3 Cheeta S et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. *Br J Psychiatry* 2004;184:41-47
- Deshauer D. Venlafaxine (Effexor): concerns about increased risk of fatal outcomes in overdose. *CMAJ* 2007;176(1):39-40
- Hawton K, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. *Br J Psychiatry* 2010;196(5):354-8.
- White NC, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. *J Med Toxicol* 2008;4:238-250.
- 4 Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized, double-blind, pbo-controlled, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2014;29(3):138-
- Mago R et al. Safety and tolerability of Levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. *Clin Drug Investig* 2013; 33(10): 761-771
- Sambunaris A et al. A phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran ER in Patients with Major Depressive Disorder. *J Clin Psychopharmacol* 2014;34(1):47-56
- Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. *J Clin Psychiatry* 2010;71(10):1259-1272
- McIntyre RS et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants. *Expert Opin Pharmacother* 2009;10 (18) :3061-3075
- Citrome L. Vortioxetine for major depressive disorder: ...a systematic review...what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2014;68:60-82
- Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KR: Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women. *Obes Res* 2001;9:544-551
- Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the NNT, NNH and LHH? *Int J Clin Pract* 2012;66:356-368
- Fava M. Weight gain and antidepressants. *J Clin Psychiatry* 2000;6 (suppl 11):37-41
- 5 Trincheri M et al. Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review. *J Sex Med* 2021;18(8):1354-1363
- Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized double-blind, plac-cont, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2013
- Mago R et al. Safety and tolerability of Levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. *Clin Drug Investig* 2013; 33(10): 761-771
- Sambunaris A et al. A phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran ER in Patients with Major Depressive Disorder. *J Clin Psychopharmacol* 2014;34(1):47-56
- Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. *Aust N Z J Psychiatry* 2009;43(9):795-808
- Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. *J Clin Psychopharmacol* 2009; 29(3): 259-266
- McIntyre RS et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants. *Expert Opin Pharmacother* 2009;10 (18) :3061-3075
- Citrome L. Vortioxetine for major depressive disorder: ...a systematic review...what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2014;68:60-82
- Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the NNT, NNH and LHH? *Int J Clin Pract* 2012;66:356-368
- Jacobson PL et al. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. *CNS Spectr* 2016; 21:367-378
- 6 Mishra A et al. Comparative efficacy and safety of pharmacological interventions for smoking cessation in healthy adults: A network meta-analysis. *Pharmacol Res* 2021;166:105478
- Howes S et al. Antidepressants for smoking cessation. *Cochrane Database Syst Rev* 2020 Apr 22;4(4):CD000031
- 7 Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized, double-blind, pbo-controlled, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2014 ;29(3):138-
- Dallal A, Chouinard G. Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. *J Clin Psychopharmacol* 1998;18(4):343-344
- Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. *Psychother Psychosom* 2015;84:72-81
- Harvey BH, Slabbert FN. New insights on the antidepressant discontinuation syndrome. *Hum Psychopharmacol* 2014;29:503-516.
- Stahl MM, Lindquist M, Pettersson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. *Eur J Clin Pharmacol* 1997;53(3-4):163-169
- 8 Beaulieu S et al. CANMAT task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. *Ann Clin Psychiatry* 2012;24(1):23-37
- 9 Bandelow B et al. WFSBP Task Force ... (2012) Guidelines for the pharmacological treatment of anxiety disorders, OCD and PTSD in primary care. *Int J Psychiatry Clin Pract* 2012;16(2):77-84
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. *Dialogues Clin Neurosci* 2017;19(2):93-107
- Fu J, Peng L, Li X. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis. *Neuropsychiatr Dis Treat* 2016;12:951-959
- Papakostas GI et al. Efficacy of bupropion and the SSRIs in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. *J Clin Psychiatry* 2008;69:1287-1292
- Blier P et al. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials. *J Affect Disord* 2017;210:27
- Qin B, Huang G, Yang Q, Zhao M, Chen H, Gao W, Yang M. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes. *BMJ Open*. 2019;9(11):e033161.
- 10 Chawla N et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials *BMJ* 2022; 376:e066084
- Dyskant M et al. SSRIs in the treatment of panic disorder: a systematic review of placebo-controlled studies. *Expert Rev Neurother* 2010;10(8):1285-1293
- Freire RC, Machado S, Arias-Carrion O, Nardi AE. Current Pharmacological Interventions in Panic Disorder. *CNS Neurol Disord Drug Targets* 2014;13(6):1057-65
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. *Dialogues Clin Neurosci* 2017;19(2):93-107
- Bandelow B et al. WFSBP Task Force ... (2012) Guidelines for the pharmacological treatment of anxiety disorders, OCD and PTSD in primary care. *Int J Psychiatry Clin Pract* 2012 Jun;16(2):77-84
- 11 Schutters SI, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. *Int Clin Psychopharmacol* 2010 Sep;25(5):302-
- Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. *Dialogues Clin Neurosci* 2017;19(2):93-107
- Bandelow B et al. WFSBP Task Force ... (2012) Guidelines for the pharmacological treatment of anxiety disorders, OCD and PTSD in primary care. *Int J Psychiatry Clin Pract* 2012 Jun;16(2):77-84
- 12 Bandelow B et al. WFSBP Task Force ... (2012) Guidelines for the pharmacological treatment of anxiety disorders, OCD and PTSD in primary care. *Int J Psychiatry Clin Pract* 2012 Jun;16(2):77-84
- 13 Walderburg E et al. Effects of duloxetine in treatment-refractory men with PTSD. *Pharmacopsychiatry* 2010;43(20):45-9
- Bandelow B et al. WFSBP Task Force ... (2012) Guidelines for the pharmacological treatment of anxiety disorders, OCD and PTSD in primary care. *Int J Psychiatry Clin Pract* 2012 Jun;16(2):77-84
- Hoskins MD et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis... *Eur J Psychotraumatol* 2021;12(1):1802920
- de Moraes Costa G et al. Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. *J Psychiatr Res* 2020 Nov;130:412-420
- 14 Maneeton N et al. Bupropion for adults with attention-deficit hyperactivity disorder: Meta-analysis of randomized, placebo-controlled trials. *Psychiatry Clin Neurosci* 2011;65 (7) , 611-7
- Maneeton N et al. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of RCTs comparison with venlafaxine. *Drug Des Devel Ther* 2013; 27(7):1053-62
- Verbeek W, Tuinier S, Bekkering GE. Antidepressants in the Treatment of Adult Attention-Deficit Hyperactivity Disorder: a Systematic Review. *Adv Ther* 2009;26(2):170-184
- Pozzi M et al. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). *Expert Opin on Emerg Drugs* 2020;25(4):395-407
- Park P et al. Use of Serotonin Norepinephrine Reuptake Inhibitors in the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatrics. *Ann Pharmacother* 2014;48(1):86-92
- 15 Calandra C et al. Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study. *Psychiatr Q* 2012;83(2):177-85
- Guerdjikova AI, McElroy SL, Winstanley EL, et al. Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. *Int J Eat Disord* 2012;45(2):281-289
- McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. *Am J Psychiatry* 2000;157:1004-1006
- McElroy SL, Hudson JI, Malhotra S, Welge JA, Keck PE. Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. *J Clin Psychiatry* 2003;15;64(7):2677

- Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: A randomized double-blind placebo-controlled comparison. *Biol Psychiatry* 2005;57(3):301
- 16 Bacaltchuk J, Hay PPJ. Antidepressants versus placebo for people with bulimia nervosa. *Cochrane Database of Syst Rev* 2003;(4):CD003391
- Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. *Arch Gen Psychiatry* 1992;49(2):139-147
- Goldstein DJ, Wilson MG, Thompson VL, Potvin JH, Rampey AH. Long-term fluoxetine treatment of bulimia nervosa. *Br J Psychiatry* 1995;166: 660-666
- Schmidt U, Cooper PJ, Essers H et al. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, placebo-controlled, and multicenter study...*J Clin Psychopharmacol* 2004;24:549-5
- 17 Thibaut, F et al. The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 Guidelines for the Pharmacological Treatment of Paraphilic Disorders. *World J Biol Psychiatry* 2020;26:1-79
- Yasin W, Ahmed S, Gouthro RV. Does Bupropion Impact More than Mood? A Case Report and Review of the Literature. *Cureus* 2019;11(3): e4277
- 18 Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized, double-blind, pbo-controlled, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2014 ;29(3):138
- Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. *Clin Ther* 2008;30(7):1206-1227
- Dago PL. Factors That Impact Choice of Antidepressant Treatment in Medically Complex Patients. *CNS Spectr* 2009;14:12(suppl 12):20-27
- 19 Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized, double-blind, pbo-controlled, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2014;29(3):138- Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. *Clin Ther* 2008;30(7):1206-1227
- Dago PL. Factors That Impact Choice of Antidepressant Treatment in Medically Complex Patients. *CNS Spectr* 2009;14:12(suppl 12):20-27
- 20 Citrome L. Vortioxetine for major depressive disorder: ...a systematic review...what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2014;68:60-82
- Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. *Clin Ther* 2008;30(7):1206-1227
- 21 Arnold LM, Hudson JI, Wang F et al. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. *Clin J Pain* 2009;25(6):461-8
- Clauw DJ. Pharmacotherapy for patients with fibromyalgia. *J Clin Psychiatry* 2008;69(suppl 2):25 - 29
- Häuser W, Eich W, Herrmann M, et al. Fibromyalgia syndrome: classification, diagnosis, and treatment. *Dtsch Arztl Zeitschrift* 2009;106:383-91
- Walitt B, Klose P, Üçeyler N, Phillips T, Häuser W. Antipsychotics for fibromyalgia in adults. *Cochrane Database Syst Rev* 2016(6): CD011804
- 22 Brecht et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with MDD and at least moderate pain of unknown etiology.... *J Clin Psychiatry* 2007;68:1707-1716
- 23 Kunz NR et al. Diabetic neuropathic pain management with venlafaxine XR. *Eur Neuropsychopharmacol* 2000;10(suppl 3):S389
- Kadrioglu AK, Sit D, Kayabasi H, et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. *J Diabetes Complications* 2008; 22:241-245
- Wasan AD, Ossanna MJ, Raskin J, et al. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients. *Curr Drug Saf* 2009; 4:22-29.
- Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. *Cochrane Database of Syst Rev* 2007(4):CD005454.
- Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. *Basic Clin Pharmacol Toxicol* 2005;96(6):399-409.
- Shah TH, Moradimehr A. Bupropion for the treatment of neuropathic pain. *Am J Hosp Palliat Care* 2010;27(5):333-6.
- 24 Arsenault P, Neron A. Le syndrome de l'intestin irritable (SII)-1. *Le Médecin du Québec* 2008;4(5):85-88
- Khalilian A et al. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. *BioPsychoSoc Med* 2021;15(1):.3.
- Ford AC et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. *Am J Gastroenterol* 2014;109:1350-65
- 25 Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. *Dialogues Clin Neurosci* 2008;10(4):409-418.
- Kim SW, Shin IS, Kim JM, Kim YC, Kim KM, Yang SJ, Yoon JS. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. *Psychiatry Clinical Neurosci* 2008;62(1):75-83
- Mago R et al. Safety and tolerability of Levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. *Clin Drug Investig* 2013; 33(10): 761-771
- Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized, double-blind, pbo-controlled, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2014 ;29(3):138
- Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the NNT, NNH and LHH? *Int J Clin Pract* 2012;66:356-368
- Clayton AH et al. An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder. *CNS Spectrums* 2009;14(4):183-95
- Wang G et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with MDD. *Neuropsychiatr Dis Treat* 2014;10:201-16.
- 26 Aronow WS, Shamiyan TA. Effects of antidepressants on QT interval in people with mental disorders. *Arch Med Sci* 2020;16(4):727-741.
- Dietle A. QTc Prolongation With Antidepressants and Antipsychotics. *US Pharm* 2015;40(11):HS34-HS40
- Citrome L. Vortioxetine for major depressive disorder: ...a systematic review...what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2014;68:60-82
- Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC: QTc prolongation, torsades de pointes, and psychotropic medications. *Psychosomatics* 2013;54(1):1-13.
- Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC: Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. *J Clin Psychiatry* 2014;75:e441-e449
- 27 Boulenger JP et al. Efficacy and safety of vortioxetine 15 and 20 mg/day: a randomized, double-blind, pbo-controlled, duloxetine-ref study in the acute treatment of adult pts with MDD. *Int Clin Psychopharmacol* 2014 ;29(3):138
- Mago R et al. Cardiovascular adverse effects of newer antidepressants. *Expert Rev Neurother* 2014;14(5): 539-551
- Mago R et al. Safety and tolerability of Levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. *Clin Drug Investig* 2013; 33(10): 761-771
- Sambunaris A et al. A phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran ER in Patients with Major Depressive Disorder. *J Clin Psychopharmacol* 2013;34:1-10
- Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. *Acta Psychiatr Scand* 2008;118:434-442
- Dunham, S et al. Which SSRI is safest for patients with CVD and major depressive disorder? *JAAPA* 2021;34(4):18-19
- 28 Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. *Am J Psychiatry* 2014;171(4):404-15.
- 29 Nagler EV et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review... with recommendations by European Renal Best Practice (ERBP). *Nephrol Dial Transplant* 2012;27(10): 3736-3745
- Mago R et al. Safety and tolerability of Levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. *Clin drug Investig* 2013 DOI 10.1007/s40261-013-0126-5
- Sambunaris A et al. A phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran ER in Patients with Major Depressive Disorder. *J Clin Psychopharmacol* 2013;34:1-10
- 30 Rottach KG, Schaner BM, Kirch MH, Zivotofsky AZ, Teufel LM, Gallwitz T, Messer T: Restless legs syndrome as side effect of second generation antidepressants. *J Psychiatr Res* 2008;43:70-75.
- Bayard M, Bailey B, Acharya D, Ambreen F, Duggal S, Kaur T, Rahman ZU, Roller K, Tuidver F: Bupropion and restless legs syndrome: a randomized controlled trial. *J Am Board Fam Med* 2011;24:422-428.
- 31 Joffe H et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. *J Clin Psychiatry* 2007;68:943-950
- Nelson HD et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA* 2006;295:2057-2071
- 32 Solmi M et al. Safety of 80 antidepressants ... in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. *World Psychiatry* 2020;19(2):214-232
- Hetrick SE et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. *Cochrane Database Syst Rev* 2021;24:5(5):CD013674
- 33 Patil AS, Kuller JA, Rhee EJJ. Antidepressants in pregnancy: a review of commonly prescribed medications. *Obstet Gynecol Surv* 2011;66 (12):777-87
- Figueroa R. Use of Antidepressants During Pregnancy and Risk of Attention-Deficit/Hyperactivity Disorder in the Offspring. *J Dev Behav Pediatr* 2010;31(8):641-8
- Grigoriadis S et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. *J Clin Psychiatry* 2013;74:e293-308
- Hallberg P, Sjöblom V. The use of SSRIs during pregnancy and breastfeeding. *J Clin Psychopharmacology* 2005;25:59-73
- Larsen ER et al. Use of psychotropic drugs during pregnancy and breastfeeding. *Acta Psychiatr Scand Suppl* 2015;(445):1-28
- Nakhai-Pour HR et al. Use of antidepressants during pregnancy and the risk of spontaneous abortion. *CMAJ* 2010;182(10):1031-7
- Reefhuis J et al. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. *BMJ* 2015;351:h3190
- St-André M. Antidépresseurs et grossesse: informer, accompagner, prescrire judicieusement. *Le Spécialiste* 2009;11(3):40-41
- Hallberg P, Sjöblom V. The use of SSRIs during pregnancy and breastfeeding. *J Clin Psychopharmacology* 2005;25:59-73
- 34 Larsen ER et al. Use of psychotropic drugs during pregnancy and breastfeeding. *Acta Psychiatr Scand Suppl* 2015;(445):1-28
- Berle J, Spigset O. Antidepressant use during breastfeeding. *Curr Womens Health Rev* 2011;7(1):28-34